BMO Capital Cuts Price target on Valeant Pharma (VRX) Following Poor 3Q Legacy Business Performance

Jefferies Cuts Price Target to $224 Following Valeant Pharma (VRX) 3Q EPS Beat

October 20, 2015 10:22 AM EDT

Jefferies maintained a Buy rating on Valeant Pharmaceuticals (NYSE: VRX), and cut the price target to $224.00 (from $294.00), following the company's 3Q results. VRX reported revenues of $2.79B vs the Street's $2.78B. EPS was reported at $2.74 vs the Street's $2.72.

Analyst David Steinberg... More

CIBC Downgrades Valeant Pharmaceuticals (VRX) to Sector Perform

October 20, 2015 7:26 AM EDT

CIBC downgraded Valeant Pharmaceuticals (NYSE: VRX) from Sector Outperform to Sector Perform.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $163.83 yesterday.

... More

Mizuho Securities Remains Neutral After Valeant Pharma (VRX) Reports 2c EPS Beat

October 20, 2015 6:46 AM EDT

Mizuho Securities reiterates a Neutral rating and $155.00 price target on Valeant Pharmaceuticals (NYSE: VRX) following the company's 3Q earnings report. Revenues of $2.80B beat consensus estimates of $2.79B and EPS of $2.74 came in $0.02 higher. Management raised full year revenue guidance to $11.0-$11.2B and... More

Market Wrap: China Data Stunts Markets; Weight Watchers Inks Major Deal; Western Digital/SanDisk Deal Nears

October 19, 2015 5:24 PM EDT

Market wrap for October 19th

End of the Day: S&P 500 up 0.6 to 2,033.66; Dow Jones up 14.6 to 17,230.54; Nasdaq up 18.8 to 4,905.47

Market Brief: U.S. markets were lower Monday following news that China's economy grew 6.9 percent in the quarter, which was the first time the metric came in below 7 percent since 2009. China's overall growth target for 2015 is about 7 percent.

U.S. housing market levels are at the highest level seen in about 10 years, according to the NAHB.

IBM and Morgan Stanley had... More

Valeant seriously considering the sale of neuro assets

October 19, 2015 9:21 AM EDT

NEW YORK (Reuters) - Valeant Pharmaceuticals International (NYSE: VRX) said on Monday that it is considering the sale of its neurological pharmaceutical business and may also spin it off or take it private.

Valeant CEO J. Michael Pearson said that the company... More

Valeant CEO sees new drug pricing environment ahead

October 19, 2015 6:13 AM EDT

By Caroline Humer

(Reuters) - Valeant Pharmaceuticals International Inc (NYSE: VRX), which has been criticized for raising drug prices and is being investigated by the U.S. government, predicted on Monday that lower price increases are ahead for the whole industry.

Valeant Chief Executive J. Michael Pearson told investors the company's 2016 outlook is based on expectations for a new pricing environment where none of its drugs have an actual price increase of more than 10 percent.

Valeant shares fell 7.7 percent, or $13.73, to close at $163.83 on the New York Stock Exchange.

Concerns... More

Valeant Pharma (VRX) Reports Q3 EPS of $0.14; Boosts FY15 EPS Outlook

October 19, 2015 6:10 AM EDT

Valeant Pharma (NYSE: VRX) reported Q3 EPS of $0.14, versus $0.81 reported last year. Revenue for the quarter came in at $2.79 billion, versus $2.06 billion reported last year.

"Today, we reported yet another consecutive quarter of strong financial results that exceeded expectations," stated J. Michael... More

Top 10 News for 10/9 - 10/16: Dell's Big Buy; Wal-mart's Dire Outlook; Twitter's Busy Week; Square's Imminent IPO

October 16, 2015 3:58 PM EDT

1. Dell affirmed speculation last weekend when it announced plans to acquire EMC Corporation (NYSE: EMC) early Monday. Under the terms of the agreement, EMC shareholders will receive $24.05 per share in cash in addition to tracking stock linked to a portion of EMCs economic interest in the VMware business. Based on the estimated number of EMC shares outstanding at the close of the transaction, EMC shareholders are expected to receive... More

Trading Radar for 10/19: Morgan Stanley (MS), IBM (IBM), Halliburton (HAL), Genuine Parts (GPC), Rambus (RMBS) Report

October 16, 2015 3:11 PM EDT

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Earnings:

Genuine Parts (NYSE: GPC) - consensus EPS $1.24
Halliburton (NYSE: HAL) - consensus EPS $0.28
Hasbro (Nasdaq: HAS) - consensus EPS $1.53
Lennox Int'l (NYSE:... More